Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
REGN Quote, Financials, Valuation and Earnings
Last price:
$790.00
Seasonality move
:
0.58%
Day range:
$785.00 - $806.18
52-week range:
$476.49 - $821.11
Dividend yield:
0.44%
P/E ratio:
19.32x
P/S ratio:
6.08x
P/B ratio:
2.72x
Volume:
974.8K
Avg. volume:
893.9K
1-year change:
19.12%
Market cap:
$84.9B
Revenue:
$14.3B
EPS (TTM):
$41.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 14.07% | 25.93% | $868.04 |
|
AMGN
Amgen, Inc.
|
$9.5B | $4.73 | 6.98% | 51.97% | $345.56 |
|
GILD
Gilead Sciences, Inc.
|
$7.7B | $1.83 | 4.29% | 81.35% | $153.08 |
|
JNJ
Johnson & Johnson
|
$24.1B | $2.46 | 7.79% | -40.82% | $231.25 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.61% | 134.27% | $1,201.63 |
|
MRK
Merck & Co., Inc.
|
$16.2B | $2.01 | 1.86% | -85.55% | $124.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$803.17 | $868.04 | $84.9B | 19.32x | $0.88 | 0.44% | 6.08x |
|
AMGN
Amgen, Inc.
|
$369.19 | $345.56 | $199B | 25.94x | $2.52 | 2.62% | 5.44x |
|
GILD
Gilead Sciences, Inc.
|
$154.98 | $153.08 | $192.3B | 22.86x | $0.79 | 2.04% | 6.61x |
|
JNJ
Johnson & Johnson
|
$243.45 | $231.25 | $586.7B | 22.04x | $1.30 | 2.11% | 6.27x |
|
LLY
Eli Lilly & Co.
|
$1,040.00 | $1,201.63 | $981.1B | 46.04x | $1.73 | 0.6% | 14.54x |
|
MRK
Merck & Co., Inc.
|
$121.41 | $124.88 | $301.3B | 16.69x | $0.85 | 2.7% | 4.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.69% | -0.011 | 3.64% | 3.29x |
|
AMGN
Amgen, Inc.
|
86.49% | -0.321 | 32.19% | 0.74x |
|
GILD
Gilead Sciences, Inc.
|
-- | 0.008 | -- | 1.31x |
|
JNJ
Johnson & Johnson
|
37.69% | -0.049 | 9.9% | 0.69x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.082 | -- | 1.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.2B | $898.6M | 13.66% | 14.93% | 23.13% | $880M |
|
AMGN
Amgen, Inc.
|
$8.1B | $3.9B | 11.96% | 102.03% | 39.83% | $961M |
|
GILD
Gilead Sciences, Inc.
|
$6.9B | $3B | 20.84% | 41.72% | 37.4% | $3.3B |
|
JNJ
Johnson & Johnson
|
$16.4B | $5.4B | 21.45% | 34.46% | 21.9% | $5.9B |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
MRK
Merck & Co., Inc.
|
$13.1B | $6.2B | 21.14% | 39.63% | 38.02% | $6.8B |
Regeneron Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns REGN or AMGN?
Amgen, Inc. has a net margin of 21.74% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 13.47%. Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93% beat Amgen, Inc.'s return on equity of 102.03%.
Company Gross Margin Earnings Per Share Invested Capital REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B AMGNAmgen, Inc.81.91% $2.45 $64.1B -
What do Analysts Say About REGN or AMGN?
Regeneron Pharmaceuticals, Inc. has a consensus price target of $868.04, signalling upside risk potential of 8.08%. On the other hand Amgen, Inc. has an analysts' consensus of $345.56 which suggests that it could fall by -6.68%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings REGNRegeneron Pharmaceuticals, Inc.17 8 0 AMGNAmgen, Inc.9 16 2 -
Is REGN or AMGN More Risky?
Regeneron Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.232% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.492%.
-
Which is a Better Dividend Stock REGN or AMGN?
Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.44%. Amgen, Inc. offers a yield of 2.62% to investors and pays a quarterly dividend of $2.52 per share. Regeneron Pharmaceuticals, Inc. pays 8.49% of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios REGN or AMGN?
Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.9B, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Regeneron Pharmaceuticals, Inc.'s net income of $844.6M is lower than Amgen, Inc.'s net income of $1.3B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 19.32x while Amgen, Inc.'s PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.08x versus 5.44x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M AMGNAmgen, Inc.5.44x 25.94x $9.9B $1.3B
-
Which has Higher Returns REGN or GILD?
Gilead Sciences, Inc. has a net margin of 21.74% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 27.55%. Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93% beat Gilead Sciences, Inc.'s return on equity of 41.72%.
Company Gross Margin Earnings Per Share Invested Capital REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B GILDGilead Sciences, Inc.86.84% $1.74 $22.6B -
What do Analysts Say About REGN or GILD?
Regeneron Pharmaceuticals, Inc. has a consensus price target of $868.04, signalling upside risk potential of 8.08%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $153.08 which suggests that it could fall by -2.49%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings REGNRegeneron Pharmaceuticals, Inc.17 8 0 GILDGilead Sciences, Inc.17 5 0 -
Is REGN or GILD More Risky?
Regeneron Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.232% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.
-
Which is a Better Dividend Stock REGN or GILD?
Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.44%. Gilead Sciences, Inc. offers a yield of 2.04% to investors and pays a quarterly dividend of $0.79 per share. Regeneron Pharmaceuticals, Inc. pays 8.49% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios REGN or GILD?
Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.9B, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Regeneron Pharmaceuticals, Inc.'s net income of $844.6M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 19.32x while Gilead Sciences, Inc.'s PE ratio is 22.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.08x versus 6.61x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M GILDGilead Sciences, Inc.6.61x 22.86x $7.9B $2.2B
-
Which has Higher Returns REGN or JNJ?
Johnson & Johnson has a net margin of 21.74% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 20.83%. Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93% beat Johnson & Johnson's return on equity of 34.46%.
Company Gross Margin Earnings Per Share Invested Capital REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B JNJJohnson & Johnson66.77% $2.10 $130.9B -
What do Analysts Say About REGN or JNJ?
Regeneron Pharmaceuticals, Inc. has a consensus price target of $868.04, signalling upside risk potential of 8.08%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.01%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings REGNRegeneron Pharmaceuticals, Inc.17 8 0 JNJJohnson & Johnson9 10 0 -
Is REGN or JNJ More Risky?
Regeneron Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.232% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.
-
Which is a Better Dividend Stock REGN or JNJ?
Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.44%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Regeneron Pharmaceuticals, Inc. pays 8.49% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios REGN or JNJ?
Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.9B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Regeneron Pharmaceuticals, Inc.'s net income of $844.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 19.32x while Johnson & Johnson's PE ratio is 22.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.08x versus 6.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M JNJJohnson & Johnson6.27x 22.04x $24.6B $5.1B
-
Which has Higher Returns REGN or LLY?
Eli Lilly & Co. has a net margin of 21.74% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 34.4%. Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About REGN or LLY?
Regeneron Pharmaceuticals, Inc. has a consensus price target of $868.04, signalling upside risk potential of 8.08%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Eli Lilly & Co. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings REGNRegeneron Pharmaceuticals, Inc.17 8 0 LLYEli Lilly & Co.18 6 0 -
Is REGN or LLY More Risky?
Regeneron Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.232% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock REGN or LLY?
Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.44%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. Regeneron Pharmaceuticals, Inc. pays 8.49% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios REGN or LLY?
Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.9B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Regeneron Pharmaceuticals, Inc.'s net income of $844.6M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 19.32x while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.08x versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M LLYEli Lilly & Co.14.54x 46.04x $19.3B $6.6B
-
Which has Higher Returns REGN or MRK?
Merck & Co., Inc. has a net margin of 21.74% compared to Regeneron Pharmaceuticals, Inc.'s net margin of 18.06%. Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B MRKMerck & Co., Inc.79.73% $1.19 $93.3B -
What do Analysts Say About REGN or MRK?
Regeneron Pharmaceuticals, Inc. has a consensus price target of $868.04, signalling upside risk potential of 8.08%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings REGNRegeneron Pharmaceuticals, Inc.17 8 0 MRKMerck & Co., Inc.15 11 0 -
Is REGN or MRK More Risky?
Regeneron Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.232% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.
-
Which is a Better Dividend Stock REGN or MRK?
Regeneron Pharmaceuticals, Inc. has a quarterly dividend of $0.88 per share corresponding to a yield of 0.44%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Regeneron Pharmaceuticals, Inc. pays 8.49% of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios REGN or MRK?
Regeneron Pharmaceuticals, Inc. quarterly revenues are $3.9B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Regeneron Pharmaceuticals, Inc.'s net income of $844.6M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio is 19.32x while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals, Inc. is 6.08x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M MRKMerck & Co., Inc.4.68x 16.69x $16.4B $3B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 17
Cooper-Standard Holdings, Inc. [CPS] is up 0.95% over the past day.
Buy
58
TPH alert for Feb 17
Tri Pointe Homes, Inc. [TPH] is down 0.15% over the past day.
Sell
20
IRON alert for Feb 17
Disc Medicine, Inc. [IRON] is up 11.47% over the past day.
